Champions Oncology Inc (OQ:CSBR)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: SUITE 619, 855 N. WOLFE STREET
BALTIMORE MD 21205
Tel: N/A
Website: https://championsoncology.com
IR: See website
<
Key People
Brady Davis
President
Ronnie Morris
Chief Executive Officer, Director
David Miller
Chief Financial Officer
Business Overview
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company's TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
Financial Overview
For the nine months ended 31 January 2024, Champions Oncology Inc revenues decreased 11% to $36.2M. Net loss increased from $2.8M to $7.2M. Revenues reflect Pharmacology services segment decrease of 71% to $11.2M, Other segment decrease of 64% to $835K. Higher net loss reflects general and administratiojn increase of 10% to $7.8M (expense), Sales and marketing - Balancing value increase of 2% to $5.1M (expense).
Employees: 230 as of Jul 15, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $62.69M as of Jan 31, 2024
Annual revenue (TTM): $49.22M as of Jan 31, 2024
EBITDA (TTM): -$6.81M as of Jan 31, 2024
Net annual income (TTM): -$9.73M as of Jan 31, 2024
Free cash flow (TTM): -$6.72M as of Jan 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 13,593,766 as of Jan 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.